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Abstract 
The assessment of ADME properties and metabolic behavior of a drug is central in drug 
discovery and drug design. The main target for studies of metabolic properties is the 
Cytochrome P450 (CYP), which is responsible for the metabolism of a majority of drugs 
on the market and consequently also involved in many drug-drug interactions. Examples 
of information and tools that could guide drug design towards favorable metabolic 
properties are structural information of the CYPs, affinity and selectivity towards the 
CYPs and the site of metabolism (SOM). The present work was initiated to use 
experimental and computational tools to study the affinity and selectivity for two of the 
most important isoenzymes, CYP2D6 and CYP3A4, and highlight the benefit of combining 
different approaches and assays to understand the metabolic properties of a drug.    
A novel computational approach resulting in an assessment of enzyme-ligand interaction 
patterns were successfully used for a comparison of different 3D-structures in order to 
highlight discriminative amino acid residues. This method could also offer an 
identification of important interactions when understanding affinity and selectivity for 
an enzyme. In order to explore affinity and selectivity factors in CYP3A4 and CYP2D6 
mediated metabolism two compounds were selected for an experimental evaluation of 
the catalytic properties of the enzyme. Based on the results from different in vitro assays 
it could be concluded that CYP3A4 was more unselective, producing metabolites as a 
result of orientations presenting many different parts of the molecules to the heme. 
CYP2D6 on the other hand showed more restricted binding modes. The combined 
information from inhibition studies and metabolite identification also gave indications 
on productive and non-productive binding modes in the two enzymes. With further 
exploration of CYP2D6, and its pharmacophore, N-dealkylation and the effect of blocking 
the SOM in CYP2D6 substrates were studied. These results were in agreement with the 
previously stated pharmacophore and also showed that the SOM for these substrates 
could be successfully assigned with a ligand-based approach, which could also be used to 
assign selectivity for CYP2D6.  
Key information, in designing compounds towards preferable metabolic properties, is 
obtained from metabolite identification or SOM determinations. I order to enhance 
metabolite identification a semi-automated software was tested that assigned the 
metabolite structure from MS raw data with high success rate. This could consequently 
be beneficial for drug design in that it enables a high throughput of metabolite 
identification data. During the course of these work important aspects to consider in 
drug design has been observed, e.g. improving metabolic stability by blocking soft spots 
tend to result in CYP inhibition. Instead of blocking soft spots the affinity for an enzyme 
could be diminished and this could be guided by the computational approach used in the 
first project. In summary, the combined knowledge from in vitro and in silico tools could 
be beneficial for the understanding of the metabolic behavior of a drug.  
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